R&D Spending Showdown: Amgen Inc. vs Gilead Sciences, Inc.

Biotech Giants' R&D Spending: A Decade of Innovation

__timestamp	Amgen Inc.	Gilead Sciences, Inc.
Wednesday, January 1, 2014	4297000000	2854000000
Thursday, January 1, 2015	4070000000	3014000000
Friday, January 1, 2016	3840000000	5098000000
Sunday, January 1, 2017	3562000000	3734000000
Monday, January 1, 2018	3737000000	5018000000
Tuesday, January 1, 2019	4116000000	9106000000
Wednesday, January 1, 2020	4207000000	5039000000
Friday, January 1, 2021	4819000000	5363000000
Saturday, January 1, 2022	4434000000	4977000000
Sunday, January 1, 2023	4784000000	6923000000

Igniting the spark of knowledge

R&D Spending Trends: Amgen Inc. vs Gilead Sciences, Inc.

In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Amgen Inc. and Gilead Sciences, Inc. have been at the forefront of this race. From 2014 to 2023, Gilead Sciences has consistently outpaced Amgen in R&D investment, with a notable peak in 2019 when Gilead's spending surged by over 78% compared to its 2014 levels. Meanwhile, Amgen's R&D expenses have shown a steady increase, peaking in 2021 with a 34% rise from 2014. This trend underscores Gilead's aggressive pursuit of new therapies, particularly in the antiviral and oncology sectors, while Amgen focuses on its core areas of biologics and biosimilars. As the biotech industry evolves, these investments will likely shape the future of healthcare innovation.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025